FDA OKs Injectable Antibiotic for Three Different Uses
The FDA approved the injectable drug ceftobiprole medocaril sodium (Zevtera) to treat adults with Staphylococcus aureus bacteremia (SAB), the agency announced Wednesday. The antibiotic prodrug is indicated for people with right-sided infective endocarditis, those with acute bacterial skin and skin structure infections (ABSSSI), and adult and pediatric patients 3 months to less than 18 years […]
A Once-Rejected Antibiotic Equals Standard for Complicated Staph Infections
WASHINGTON — Investigational ceftobiprole was just as effective as daptomycin for bacterial bloodstream infections caused by Staphylococcus aureus bacteremia, the phase III ERADICATE trial demonstrated. In the randomized head-to-head comparison, post-treatment success at 70 days was 69.8% with ceftobiprole and 68.7% with daptomycin, meeting prespecified criteria for non-inferiority, Thomas Holland, MD, of Duke University in […]